Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
Pfizer 's PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for ambulatory boys with Duchenne muscular dystrophy (DMD) failed to meet the primary endpoint as well as key secondary endpoints. The FDA approved AstraZeneca 's AZN type-II diabetes (T2D) medicine, Farxiga, for pediatric patients. AbbVie ABBV announced that it is in-licensing exclusive global rights to a next-generation TL1A antibody for the treatment of inflammatory bowel disease (IBD) from a Chinese biotech. Recap of the Week's Most Important Stories FDA Panel Unanimously Endorses Lilly's Donanemab: The FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0 unanimously recommending approval of Lilly's Alzheimer's disease drug, donanemab. The committee said that data from clinical studies on donanemab demonstrated substantial evidence of efficacy and clinically meaningful slowing of disease progression for early symptomatic Alzheimer's patients. Overall,
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Sarepta's Elevidys secures US label expansion for DMD [Yahoo! Finance]Yahoo! Finance
- Sarepta Jumps on Broad Approval for Muscular Dystrophy Drug [Yahoo! Finance Canada]Yahoo! Finance Canada
- Dyspareunia Treatment Market to Hit $1,035.4 million by 2031, at a CAGR of 4.6%, says Coherent Market Insights [Yahoo! Finance]Yahoo! Finance
- Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi's Executive Committee [Yahoo! Finance]Yahoo! Finance
- Sarepta Jumps on Broad Approval for Muscular Dystrophy Drug [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 5/1/24 - Beat
PFE
Sec Filings
- 6/17/24 - Form 4
- 6/17/24 - Form 4
- 6/11/24 - Form 11-K
- PFE's page on the SEC website